Galmed Pharmaceuticals Ltd.

GLMD · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$7,517-$6,912-$17,866-$32,467
Dep. & Amort.$83$31$35$42
Deferred Tax$0$0$0$84
Stock-Based Comp.$531$892$1,296$1,886
Change in WC-$728$132-$2,451-$2,450
Other Non-Cash$1,751-$280$485$13
Operating Cash Flow-$5,880-$6,137-$18,501-$32,892
Investing Activities
PP&E Inv.$0$0-$4-$11
Net Acquisitions$0-$1,500-$18$0
Inv. Purchases-$6,365-$6,333-$3,873-$13,569
Inv. Sales/Matur.$5,504$8,633$21,440$25,043
Other Inv. Act.-$250$0$18-$1
Investing Cash Flow-$1,111$800$17,563$11,462
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$8,786$6,185$70$17,368
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$8,786$6,185$70$17,368
Forex Effect$0$0$0$0
Net Chg. in Cash$1,795$848-$868-$4,062
Supplemental Information
Beg. Cash$2,978$2,130$2,998$7,060
End Cash$4,773$2,978$2,130$2,998
Free Cash Flow-$5,880-$6,137-$18,505-$32,903
Galmed Pharmaceuticals Ltd. (GLMD) Financial Statements & Key Stats | AlphaPilot